A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors
What is the purpose of this trial?
This research study is studying a new drug, NC762, as a possible treatment for advanced or metastatic solid tumors.
- Trial withNextCure, Inc.
- Start Date07/08/2022
- End Date10/01/2024
- Last Updated07/12/2022
- Study HIC#2000030669